Table 1. Study characteristics, patient population.
| Name, year | Diagnosis in the study population | Design | Consecutive | n (Eyes)a | Mean age (years) | Female proportion |
|---|---|---|---|---|---|---|
| Nowomiejska et al22 | Wet AMD (36), healthy subjects (23) | Diagnostic case–control study | n.r. | 59 | Wet AMD 72.0, healthy subjects 68.3 | Wet AMD 0.67, healthy subjects 0.44 |
| Alster et al23 | CNV (65), intermediate AMD (57) | Prospective, comparative, clinical study | + | 122 | Median: CNV 77, intermediate AMD 76 | CNV 0.6, intermediate AMD 0.53 |
| Preferential hyperacuity perimeter (PHP) Research Group, Goldstein et al6 | CNV (19), geographic atrophy (27)b, intermediate AMD (20)b, early AMD (51)b, health subjects (33) | Diagnostic case–control study | + | 150c | 73.6 (based on 171 patients) | 0.54 (Based on 171 patients) |
| Isaac et al24 | CNV (10), intermediate AMD (18), early AMD (22), healthy subjects (15) | Diagnostic case–control study | n.r. | 65 | CNV 71.7, intermediate AMD 66.0, early AMD 67.3, healthy subjects 64.7 | CNV 0.6, intermediate AMD 0.444, early AMD 0.545, healthy subjects 0.533 |
| Lai et al25 | CNV (10), late AMD (10)b, health subjects (21) | Diagnostic case–control study | n.r. | 41 | n.r. | n.r. |
| Loewenstein et al26 | CNV (32), geographic atrophy (23)b, AMD with high-risk characteristics (HRC) (35)b, early AMD with non-HRC (18)b, healthy subjects (51) | Diagnostic case–control study | + | 159 | 74 | 0.59 |
| Loewenstein et al (retrospective)27 | Recent onset CNV (34), intermediate AMD (43) | Diagnostic case–control study | n.r. | 77 | Median 76 | CNV 0.58, intermediate AMD 0.30 (1 unknown) |
| Loewenstein et al (prospective)27 | Recent onset CNV (32), intermediate AMD (22) | diagnostic case–control study | + | 54 | Median: CNV 78, intermediate AMD 73.5 | CNV 0.71 (1 unknown), intermediate AMD 0.60 (2 unknown) |
| Mathew and Sivaprasad28 | First test: CNV (59), no CNV (41), Second test: CNV (68), no CNV (32) | Prospective cohort study | n.r. | 100 | 80.2 | 0.61 |
| Robinson et al29 | Wet AMD (29 eyes), dry AMD (34)b, healthy subjects (27 eyes) | Diagnostic case–control study | n.r. | 90 | Wet AMD 77.7, dry AMD 75.9 | AMD patients 0.56 |
| Arimura et al30 | AMD (19; 6 dry type and 13 wet type), idiopathic macular hole (M-hole) (22)b, idiopathic epiretinal membrane (ERM) (39)b, healthy subjects (51) | Diagnostic case–control study | n.r. | 131 | AMD 67.6, M-hole 63.1, ERM 64.1, healthy subjects 68.0 | AMD 0.16, M-hole 0.46, ERM 0.59, healthy subjects 0.57 |
| Klatt et al31 | Classic CNV (35), occult CNV (38), intermediate AMD (13)b, retinopathia centralis serosa (RCS) (11)b, epiretinal gliosis (13)b, macular foramen (23)b, healthy subjects (20) | Diagnostic case–control study | n.r. | 153 | Occult CNV 75.9, classic CNV 74.2, intermediate AMD 72.4, RCS 41.3, epiretinal Gliosis 71.7, macular foramen 67.9 | Occult CNV 0.58, classic CNV 0.57, intermediate AMD 0.54, RCS 0, epiretinal gliosis 0.62, macular foramen 0.82 |
| Kampmeier et al32 | Classic CNV (11), occult CNV (25), retinal pigment epithelium elevation (9), non-neovascular AMD (95)b, healthy subjects 34 | Diagnostic case–control study | + | 174 | Median: CNV+non-neovascular AMD 68 | CNV+non-neovascular AMD 0.49 |
Abbreviation: n.r., not reported.
a
Includes all subsets studied.
b
Excluded from analysis.
c
Patients (179) were enrolled in the study. Mean age and female proportion were reported for 171 patients. For 150 patients results were reported.